Skip to main content
MADRIGAL PHARMACEUTICALS, INC. logo

MADRIGAL PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · MDGL ISIN · US5588681057 LEI · 549300CHIMT2EUSNJB60 US Manufacturing
Open in API
Filings indexed 1,022 across all filing types
Latest filing 2023-09-13 Director's Dealing
Country US United States of America
Listing US MDGL

About MADRIGAL PHARMACEUTICALS, INC.

https://www.madrigalpharma.com/

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious and progressive liver disease with high unmet medical need. The company's research led to the first U.S. Food and Drug Administration (FDA)-approved treatment for MASH. Madrigal's therapeutic goal is to halt or reverse liver scarring (fibrosis) and resolve the disease before patients experience severe complications, including cirrhosis, liver failure, and the need for transplantation.

Recent filings

Filing Released Lang Actions
3
Director's Dealing
2023-09-13 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is used for current reports on significant events. The content specifically details the appointment of a new Chief Executive Officer and Class II Director, including compensation agreements and severance arrangements. It also notes the departure of the previous CEO from that role. This type of filing is an announcement of changes in the company's board of directors and senior management. There are no financial statements or earnings data presented, so it is not an earnings release or annual/interim report. The document fits the category of Board/Management Information (MANG). The document length is 7190 characters, which is sufficient for a detailed announcement rather than a brief notice or report publication announcement.
2023-09-13 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, which is used to announce unscheduled material events or corporate changes. The text indicates that the company issued a press release about the FDA accepting their New Drug Application and granting Priority Review. The document includes the press release as an exhibit but does not contain detailed financial statements or comprehensive report data. The length is 3270 characters, which is relatively short and consistent with an announcement rather than a full report. There is no indication of quarterly or annual financial results, management discussion, or audit information. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2023-09-13 English
S-8
Share Issue/Capital Change Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by Madrigal Pharmaceuticals, Inc. It registers shares of common stock reserved for issuance under an inducement plan. The text includes detailed information about the plan, incorporation by reference of other filings, and legal indemnification provisions. Form S-8 is a specific SEC filing used to register securities to be offered under employee benefit plans. This is not a financial report, earnings release, or management discussion, but a registration statement related to share issuance under an employee plan. Therefore, it fits best under the category of Share Issue/Capital Change (SHA). The document length and content confirm it is the actual filing, not just an announcement or certification.
2023-09-11 English
JHG PLC OWNS 10%
Major Shareholding Notification
2023-09-08 English
SC 13D/A
Major Shareholding Notification
2023-08-08 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.